Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04EAT
|
|||
| Former ID |
DIB013130
|
|||
| Drug Name |
MCS-110
|
|||
| Synonyms |
Colony stimulating factor-1 inhibiting antibody (cancer), Novartis; Anti-CSF-1 antibody (cancer), Novartis
Click to Show/Hide
|
|||
| Indication | Bone metastases [ICD-11: 2D50; ICD-10: C79.5; ICD-9: 198.5] | Phase 2 | [1] | |
| Tenosynovial giant cell tumour [ICD-11: 2F7B; ICD-10: D48.0] | Phase 2 | [2] | ||
| Triple negative breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [2] | ||
| Advanced malignancy [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1/2 | [2] | ||
| Breast cancer [ICD-11: 2C60-2C65] | Phase 1 | [3] | ||
| Company |
Novartis pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Colony stimulating factor-1 receptor (CSF-1R) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01643850) MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.